Please log in to take part in the discussion (add own reviews or comments).
Cite this publication
More citation styles
- please select -
%0 Conference Paper
%1 fabre2018omtx705
%A Fabre, Myriam
%A Ferrer, Cristina
%A Dominguez-Hormaetxe, Saioa
%A Kontermann, Roland
%A Pfizenmaier, Klaus
%A Seifert, Oliver
%A Lopez-Casas, Pedro Pablo
%A Abbas, Muhammad
%A Richter, Wolfgang
%A Simón, Laureano
%A Hidalgo, Manuel
%B Abstract Book of the 43rd ESMO Congress (ESMO 2018)
%C Elsevier
%D 2018
%I Oxford Univ. Press
%K
%N 29, Suppl. 8
%P 414
%T OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments
@inproceedings{fabre2018omtx705,
added-at = {2023-08-31T15:13:58.000+0200},
address = {Elsevier},
affiliation = {Fabre, M.; Ferrer, C.; Dominguez-Hormaetxe, S.; Simon, L., Oncomatryx Biopharma SL, R&D Dept, Derio, Spain.
Kontermann, R.; Pfizenmaier, K.; Seifert, O., Stuttgart Univ, Inst Cell Biol & Immunol, Stuttgart, Germany.
Lopez-Casas, P. P., CNIO, Gastrointestinal Canc Clin Res Unit, Madrid, Spain.
Abbas, M.; Richter, W., Tube Pharmaceut GmBH, R&D Dept, Vienna, Austria.
Hidalgo, M., Harvard Med Sch, Dept Med, Boston, MA 02115 USA.},
author = {Fabre, Myriam and Ferrer, Cristina and Dominguez-Hormaetxe, Saioa and Kontermann, Roland and Pfizenmaier, Klaus and Seifert, Oliver and Lopez-Casas, Pedro Pablo and Abbas, Muhammad and Richter, Wolfgang and Simón, Laureano and Hidalgo, Manuel},
biburl = {https://puma.ub.uni-stuttgart.de/bibtex/26468bb206310f8f60b46e88a1dda19ae/puma-wartung},
booktitle = {Abstract Book of the 43rd ESMO Congress (ESMO 2018)},
eventdate = {2018-10-19/2018-10-23},
eventtitle = {43rd ESMO Congress (ESMO)},
howpublished = {Abstract},
interhash = {e4c4405041f63e012b76d6ce7a4ef5c3},
intrahash = {6468bb206310f8f60b46e88a1dda19ae},
keywords = {},
language = {eng},
number = {29, Suppl. 8},
pages = 414,
publisher = {Oxford Univ. Press},
research-areas = {Oncology},
series = {Annals of oncology},
timestamp = {2023-08-31T13:13:58.000+0200},
title = {OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments},
unique-id = {ISI:000459277302340},
venue = {München},
year = 2018
}